Barclays PLC Immucell Corp Transaction History
Barclays PLC
- $854 Billion
- Q3 2025
A detailed history of Barclays PLC transactions in Immucell Corp stock. As of the latest transaction made, Barclays PLC holds 7 shares of ICCC stock, worth $38. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7Holding current value
$38% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ICCC
# of Institutions
28Shares Held
1.28MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA309KShares$1.7 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny157KShares$865,0890.0% of portfolio
-
Cresset Asset Management, LLC Chicago, IL132KShares$726,0050.0% of portfolio
-
Morgan Stanley New York, NY105KShares$578,1380.0% of portfolio
-
Bleichroeder LP New York, NY102KShares$558,7670.16% of portfolio
About IMMUCELL CORP
- Ticker ICCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 7,746,860
- Market Cap $42.6M
- Description
- ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive ...